Japan
· Delayed Price · Currency is JPY Chugai Pharmaceutical Company Description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan.
Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
| Country | Japan |
| Founded | 1925 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 7,604 |
| CEO | Osamu Okuda |
Contact Details
Address: 2-1-1 Nihonbashi-Muromachi Chuo, 103-8324 Japan | |
| Phone | 81 3 3281 6611 |
| Website | chugai-pharm.co.jp |
Stock Details
| Ticker Symbol | 4519 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3519400000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Osamu Okuda | Chief Executive Officer |
| Iwaaki Taniguchi | Chief Financial Officer |
| Toshiya Sasai | Head of Investor Relations |